Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Nov 10, 2017
The California HIV/AIDS Research Program (CHRP) is proud to be funding the largest demonstration project of its kind in the U.S., to determine the efficacy, acceptability, and pharmacokinetics of HIV pre-exposure prophylaxis (PrEP) medication among transgender persons. CHRP has invested $9.4 million in three research studies across the state, recognizing that the people in the transgender community deserve dedicated and substantial resources to promote their health and protect their lives. The studies each use different techniques, such as providing PrEP and hormonal therapy together at a single clinic visit, or an in-depth pharmacokinetic analysis to determine whether the two treatments interact, or a custom text messaging app to communicate with providers and peer support. In the video, researchers, consumers, and health care providers offer their perspectives on why this research is important, and how members of the community can participate. This video premiered on 11th November 2017 at the National Transgender Health Summit.